Study sheds light on what E. coli genes are doing inside the body during infection

Urinary tract infections are not only a painful, recurring problem for millions of women, they’re getting more dangerous  as bacteria develop resistance to the most common treatments.  Scientists from the University of Michigan, however, have moved one step  closer to a vaccine that could prevent a majority of urinary tract  infections, which are caused by E. coli bacteria.

The researchers studied  how bacteria operate using a genetic technique rarely used to look at  infections in human hosts and discovered key differences between how E. coli genes behave in women and how they behave in the mice that are often  used in experiments.

Olympus cellSens Dimension Multi-position Solution module

Olympus has today released the Multi-position Solution module for its cellSens Dimension software. The module works in tandem with the cellSens Dimension Multiple Image Alignment (MIA) tool to facilitate the simple creation of high-resolution, panoramic images capable of covering the complete microscope stage. The Multi-position software puts the user in the best position possible to accurately and automatically investigate large or complicated samples without sacrificing magnification power or image quality.

Genotypic Technology awarded SAP ACE Awards 2010 for Customer Excellence

Alok Goyal, COO, SAP India, and
Dr Sudha Rao, VP, Genotypic Technology Pvt Ltd

Genotypic Technology today announced that it has been awarded the SAP ACE (Awards for Customer Excellence) 2010 and adjudged as a “Best Run Business for on-demand implementation”.

The SAP ACE award honours organizations for business value creation through innovative use of IT, in every major industry vertical. This award for the best on-demand implementation was instituted by SAP for the first time this year. Genotypic gets the honour of being the very first organization in the field of genomics in India to get the ACE award, and the first ever in this category.

Enhanced search speeds and increased accuracy of analyses

SORCERER provides the SBMRI team with
enhanced search speeds and increased accuracy

Sage-N Research Inc today announced that The Sanford-Burnham Medical Research Institute (SBMRI), a private, non-profit based research institute dedicated to finding cures for human disease, has implemented the Sage-N SORCERER Enterprise proteomics platform.

The company will use the system to enhance the speed of data searches and increase data generation for its proteomics projects which range from the identification of proteins in gel bands to quantitative total proteome and total phosphoproteome analyses.

SBMRI's Proteomics Facility offers liquid chromatography-tandem mass spectrometry (LC-MS/MS) based proteomics services to support the Institute's researchers.

Over recent years the facility has used a variety of search engines to undertake database searches and has recently chosen to implement the Sage-N Sorcerer Enterprise platform for its large-scale analyses.

Discovery of small molecule and therapeutic antibody leads against GPCR targets

Heptares Therapeutics Ltd, the drug discovery company focused on G-protein-coupled receptor (GPCR) targets, provides a positive update on the progress it has made in the discovery of novel therapeutic leads against important GPCR targets.

Since its founding in 2007, Heptares has established an integrated drug discovery capability around its StaR (stabilised receptor) technology platform and now employs more than 40 people at its fully equipped research facilities at BioPark.

Heptares’ StaR technology1 enables its scientists to stabilise GPCRs in functionally relevant conformations that retain their drug-binding characteristics. Subsequently, the Company has shown that these StaRs can be used with powerful but hitherto unavailable discovery techniques, including X-ray structure-based design, receptor binding kinetics analysis, fragment screening, and antibody generation.